Washington, D.C. 20549


Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: September 15, 2022
Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

On September 15, 2022, Legend Biotech Corporation (“Legend Biotech”) issued a press release announcing the date and time of its Research & Development Day.

The press release announcing the details of the R&D Day is attached to this Form as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Form 6-K, excluding Exhibit 99.1, is hereby incorporated by reference into Legend Biotech’s Registration Statements on Form F-3 (Registration Nos. 333-257625 and 333-257609) and Legend Biotech’s Registration Statement on Form S-8 (Registration No. 333-239478).


Exhibit              Title

99.1                    Press Release, dated September 15, 2022

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 15, 2022
/s/ Ying Huang
Ying Huang, Ph.D.
Chief Executive Officer

Exhibit 99.1

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

SOMERSET, N.J.--(BUSINESS WIRE)--September 15, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please click here to register for the event.

The event will feature a comprehensive overview of our platforms and the latest developments in our pipeline through presentations from members of Legend’s senior leadership team:

  • Ying Huang, Ph.D., Chief Executive Officer
  • Guowei Fang, Ph.D., Senior Vice President, Global Head of Research and Early Development
  • Lida Pacaud, M.D., Vice President, Clinical Development
  • Steve Gavel, Vice President, Commercial Development, US & Europe

A live webcast and presentation will be available to investors and other interested parties on the Legend Biotech website under “Events and Presentations”. A replay of the webcast can be viewed as early as 24 hours after the event.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Source: Legend Biotech


Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

Crystal Chen, Manager, Investor Relations, Legend Biotech

Tina Carter, Corporate Communications Lead, Legend Biotech
(908) 331-5025